ZURICH ¨C Drugs being repurposed in hopes they will help against COVID-19 cost relatively little to make but may prove challenging to produce in quantities needed for a pandemic, a drug pricing expert has said.
¡°Any pharmaceutical company manufacturing any treatment currently in clinical trials against coronavirus needs a clear plan to upscale production massively,¡± said Andrew Hill, a research fellow at the University of Liverpool.
¡°Otherwise, supplies of these drugs could quickly run out.¡±
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.